UNI-BIO SCIENCE GROUP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.089 HKD | +4.71% |
|
+7.23% | +23.61% |
| Mar. 27 | Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 14 | Uni-Bio Science's Profit to Climb in 2023 | MT |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 924.7 | 550 | 1,006 | 735 | 533.4 | 458.3 |
| Enterprise Value (EV) 1 | 803.5 | 524.7 | 920.4 | 661.4 | 448.7 | 372.4 |
| P/E ratio | -2.91 x | -3.97 x | 402 x | -10.3 x | -27.1 x | 11.9 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.91 x | 4.07 x | 4.81 x | 3.52 x | 1.51 x | 1.04 x |
| EV / Revenue | 5.13 x | 3.88 x | 4.39 x | 3.17 x | 1.27 x | 0.85 x |
| EV / EBITDA | -15.6 x | -5 x | -15.4 x | -36.4 x | 41.2 x | 6.26 x |
| EV / FCF | -12.7 x | -10.2 x | -22.3 x | -122 x | 12.9 x | 14.4 x |
| FCF Yield | -7.87% | -9.84% | -4.49% | -0.82% | 7.76% | 6.93% |
| Price to Book | 2.69 x | 2.73 x | 4.17 x | 3.88 x | 3.06 x | 2.35 x |
| Nbr of stocks (in thousands) | 6,164,968 | 6,179,968 | 6,410,768 | 6,391,008 | 6,349,768 | 6,364,768 |
| Reference price 2 | 0.1500 | 0.0890 | 0.1570 | 0.1150 | 0.0840 | 0.0720 |
| Announcement Date | 4/23/18 | 4/12/19 | 4/27/20 | 4/26/21 | 4/7/22 | 4/20/23 |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 156.5 | 135.3 | 209.4 | 208.8 | 353.4 | 440.3 |
| EBITDA 1 | -51.64 | -105 | -59.64 | -18.19 | 10.88 | 59.53 |
| EBIT 1 | -81.89 | -125.9 | -78.26 | -36.95 | -4.833 | 47.24 |
| Operating Margin | -52.34% | -93.09% | -37.36% | -17.7% | -1.37% | 10.73% |
| Earnings before Tax (EBT) 1 | -278.3 | -138.4 | 5.14 | -70.94 | -20.01 | 43.29 |
| Net income 1 | -279.3 | -138.6 | 2.459 | -71.32 | -19.59 | 38.51 |
| Net margin | -178.5% | -102.45% | 1.17% | -34.16% | -5.54% | 8.75% |
| EPS 2 | -0.0515 | -0.0224 | 0.000391 | -0.0111 | -0.003100 | 0.006054 |
| Free Cash Flow 1 | -63.25 | -51.63 | -41.34 | -5.407 | 34.81 | 25.8 |
| FCF margin | -40.42% | -38.17% | -19.74% | -2.59% | 9.85% | 5.86% |
| FCF Conversion (EBITDA) | - | - | - | - | 319.97% | 43.34% |
| FCF Conversion (Net income) | - | - | - | - | - | 67% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/23/18 | 4/12/19 | 4/27/20 | 4/26/21 | 4/7/22 | 4/20/23 |
1HKD in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 121 | 25.3 | 86.1 | 73.5 | 84.7 | 85.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -63.3 | -51.6 | -41.3 | -5.41 | 34.8 | 25.8 |
| ROE (net income / shareholders' equity) | -70.8% | -50.9% | 1.11% | -33.1% | -10.8% | 20.9% |
| ROA (Net income/ Total Assets) | -11.5% | -24.9% | -18.2% | -8.41% | -1.16% | 10.5% |
| Assets 1 | 2,422 | 557 | -13.55 | 848 | 1,687 | 365.3 |
| Book Value Per Share 2 | 0.0600 | 0.0300 | 0.0400 | 0.0300 | 0.0300 | 0.0300 |
| Cash Flow per Share 2 | 0 | 0.0100 | 0.0100 | 0 | 0.0100 | 0.0200 |
| Capex 1 | 24.6 | 1.65 | 8.1 | 3.44 | 8.43 | 28.4 |
| Capex / Sales | 15.71% | 1.22% | 3.87% | 1.65% | 2.39% | 6.46% |
| Announcement Date | 4/23/18 | 4/12/19 | 4/27/20 | 4/26/21 | 4/7/22 | 4/20/23 |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +23.61% | 66.92M | |
| -4.59% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 690 Stock
- Financials Uni-Bio Science Group Limited
